Application error: a client-side exception has occurred (see the browser console for more information).

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

His experiment laid the foundation for modern clinical trials—structured studies on humans to assess the safety and effectiveness of treatments, vaccines, or preventive interventions.

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Click here to read my analysis.

More information: Eunice S. Wang et al, Ziftomenib in relapsed/refractory (R/R) NPM1 -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET ...

Accordingly, I suggest renaming this first phase of diagnostic radiopharmaceutical development as a phase A (acquisition optimization) trial. The primary aim of the next phase of conventional drug ...